Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 303.01M P/E - EPS this Y -1,553.30% Ern Qtrly Grth -
Income -9.06M Forward P/E -2.14 EPS next Y 27.40% 50D Avg Chg -6.00%
Sales 58.75M PEG 0.02 EPS past 5Y - 200D Avg Chg -17.00%
Dividend N/A Price/Book 2.77 EPS next 5Y -283.60% 52W High Chg -38.00%
Recommedations 1.70 Quick Ratio 4.28 Shares Outstanding 62.56M 52W Low Chg 67.00%
Insider Own 2.61% ROA -36.33% Shares Float 52.17M Beta 2.11
Inst Own 100.65% ROE -6.15% Shares Shorted/Prior 8.60M/5.60M Price 4.90
Gross Margin -197.55% Profit Margin -15.42% Avg. Volume 504,966 Target Price 24.80
Oper. Margin -460.39% Earnings Date May 7 Volume 1,298,494 Change 0.41%
About MacroGenics, Inc.

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MacroGenics, Inc. News
04/19/24 We're Hopeful That MacroGenics (NASDAQ:MGNX) Will Use Its Cash Wisely
04/03/24 MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
03/14/24 MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript
03/09/24 12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
03/08/24 Q4 2023 MacroGenics Inc Earnings Call
03/08/24 MacroGenics (MGNX) Q4 2023 Earnings Call Transcript
03/07/24 Macrogenics Inc (MGNX) Reports Strong Financial Position and Advancements in Cancer Treatment ...
03/07/24 MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates
03/07/24 MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
03/06/24 Insider Sell: COO Eric Risser Sells 41,159 Shares of Macrogenics Inc (MGNX)
08:09 AM Are Investors Undervaluing MacroGenics, Inc. (NASDAQ:MGNX) By 48%?
03/01/24 MacroGenics to Participate in Upcoming Investor Conferences
02/29/24 Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for
02/27/24 MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
04:30 PM MacroGenics to Participate in Upcoming Investor Conference
07:19 AM MacroGenics (MGNX) Surges 6.8%: Is This an Indication of Further Gains?
01/15/24 The 3 Most Undervalued Biotech Stocks to Buy in January
12/17/23 7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
12/12/23 Shareholders in MacroGenics (NASDAQ:MGNX) are in the red if they invested three years ago
11/07/23 Q3 2023 MacroGenics Inc Earnings Call
MGNX Chatroom

User Image M_T_D Posted - 17 hours ago

@FlynancialAnalyst Have you looked at $MGNX?

User Image OpenOutcrier Posted - 04/25/24

RECAP 4/25 Unusual Puts: $MSFT Sep 395 P $MGNX Jun 10 P $ON May 55 P $CSCO May 45.5 P Live Breaking trading news www.openoutcrier.com

User Image 1LIFE2LIVE Posted - 04/22/24

$MGNX Starter on this morning’s weakness; The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies (Incyte Corporation, Gilead Sciences, Sanofi, Eversana and ZaiLab). Eventually will be acquired by one of its partners and or Big Pharma at a premium to current market price; Patience will pay; Long.

User Image Herbicheck Posted - 04/11/24

$MGNX stopped out, didn’t have the juice

User Image AboveTheHorizon Posted - 04/10/24

$MGNX unusual call option activity today.

User Image That1Foolio Posted - 04/10/24

$MGNX Great sideways action.

User Image WallStJesus Posted - 04/10/24

$MGNX UNUSUAL BULL BET

User Image Quantumup Posted - 04/09/24

TD Cowen⬆️ $MGNX Buy was Hold, says they "Believe There Is Favorable Risk/Reward Heading Into The Efficacy Update By The End Of May" TD/KOLs believe vobra duo could@least prove > chemo alone/b used as an important part of the 2L+ mCRPC arsenal w/ $1.8B pot:

User Image basscat12 Posted - 04/09/24

$MYMD $MGNX $CGNT Pre-Market Gap Up, delayed, courtesy barchart, presented here for @Vegas1 to help follow the money!

User Image insiderbuyingselling Posted - 04/08/24

$MGNX new insider selling: 51395 shares. http://insiderbuyingselling.com/?t=MGNX

User Image Herbicheck Posted - 04/05/24

$MGNX buying at break of 19.00 Monday

User Image biolover Posted - 04/05/24

$MGNX this is going over 20 by EOD . Pressure is enormous

User Image Fullratio Posted - 04/05/24

$MGNX total assets is 105% more than its total liabilities: https://fullratio.com/stocks/nasdaq-mgnx/macrogenics

User Image IsabellaDC Posted - 04/05/24

$MGNX 🐔 | Cluck cluck!

User Image GSP Posted - 04/05/24

$SPY $MGNX $CZOO $MNMD $CADL

User Image Landsmann Posted - 04/05/24

$MGNX this is where you need to short

User Image Aigner_Andreas Posted - 04/05/24

TF BUY $MGNX at 17.78 : 17.14 SmallCap 78% Shp 2.2 S 2.77 N 0.98 RSI 60.03% SRSI 100% ADXR 34.92 #stocks #trading #finance #market

User Image ClassifiedTrades Posted - 04/04/24

$TSLA $MGNX $CADL BOOOOMMM ! What a day !!!!

User Image Bigeyes2 Posted - 04/04/24

$MGNX Swing

User Image Trigga_tha_Gambler Posted - 04/04/24

$MGNX 🚀

User Image GSP Posted - 04/04/24

$MGNX had a very impressive day in a weak tape for $SPY. It makes our watch list for Friday.

User Image GSP Posted - 04/04/24

Day Trading Watch List Video for April 5th: $SPY $CADL $MNMD $CZOO $MGNX Watch here: https://greatstockpix.com/april-5th-day-trading-watch-list/

User Image ClassifiedTrades Posted - 04/04/24

$CADL BOOOOMMMMM here timestamps !!! BOOOOMMMM $MGNX $TSLA

User Image ClassifiedTrades Posted - 04/04/24

$CADL going for the final target ;) $LEVI $MGNX

User Image biolover Posted - 04/04/24

$MGNX can we form discontent investor group here. Maybe add like to potentially communicate to reach out to company or may he to someone like Carl Icahn. If we have good leadership ( such as the ones at Viking therapeutics ) this should be multi billion MC by now. The basic scientist group is great but the clinical leadership is a disaster

User Image biolover Posted - 04/04/24

$MGNX he even shelved the pd1 lag3 an that other large pharma are dying to have. What an ignorant CEO and board.

User Image biolover Posted - 04/04/24

$MGNX pd1 ctla4 bispecific is more potent than Merck or bms drugs. If we just have a CEO who knows how to design trials such as lung or kidney or melanoma against pembrolizumab or nivolumab. Much more valuable assets that duo drug that lifted today even on safety data. We need an activist investor. .

User Image _StockTrader Posted - 04/04/24

Real-Time Stock Data $MGNX Price: 19.82 Volume: 4545248 Market Cap: 1126585472 PE Ratio: -17.691177 Powered by: AITX

User Image Trigga_tha_Gambler Posted - 04/04/24

$MGNX Loadin' up!

User Image IsabellaDC Posted - 04/04/24

$MGNX Let's share my chicken lines here

Analyst Ratings
TD Cowen Buy Apr 9, 24
JMP Securities Market Outperform Apr 4, 24
Citigroup Buy Mar 11, 24
JMP Securities Outperform Mar 11, 24
HC Wainwright & Co. Neutral Mar 11, 24
BMO Capital Outperform Mar 8, 24
Stifel Buy Mar 8, 24
Barclays Overweight Mar 8, 24
BTIG Buy Mar 4, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Bonvini Ezio Sr VP, Research & CS.. Sr VP, Research & CSO Jan 19 Sell 12 13,316 159,792 87,984 01/22/24
BIOTECH TARGET N V 10% Owner 10% Owner Feb 14 Buy 5.0652 500,000 2,532,600 9,579,963 02/16/23
BIOTECH TARGET N V 10% Owner 10% Owner Dec 23 Buy 5.75 400,000 2,300,000 8,929,963 12/28/22
Koenig Scott President and CEO President and CEO May 16 Option 1.51 53,265 80,430 1,049,636 05/17/22
Karrels James SVP, CFO and Secreta.. SVP, CFO and Secretary Mar 28 Option 1.51 8,316 12,557 151,776 03/28/22
Risser Eric Blasius Chief Operating Offi.. Chief Operating Officer Mar 04 Option 0.94 500 470 44,968 03/04/22
BIOTECH TARGET N V 10% Owner 10% Owner Sep 20 Buy 20.44 600,000 12,264,000 6,875,564 09/20/21
Peters Jeffrey Stuart General Counsel General Counsel Mar 09 Option 11.5 21,749 250,114 21,749 03/09/21
Peters Jeffrey Stuart General Counsel General Counsel Mar 09 Sell 26.5 21,749 576,348 03/09/21
Risser Eric Blasius Sr VP & Chief Busine.. Sr VP & Chief Business Officer Dec 01 Option 1.51 500 755 44,968 12/01/20
Risser Eric Blasius Sr VP & Chief Busine.. Sr VP & Chief Business Officer Dec 01 Sell 23.35 500 11,675 44,468 12/01/20
Risser Eric Blasius Sr VP & Chief Busine.. Sr VP & Chief Business Officer Oct 29 Option 1.51 1,500 2,265 45,968 10/29/20
Risser Eric Blasius Sr VP & Chief Busine.. Sr VP & Chief Business Officer Oct 29 Sell 20.69 1,500 31,035 44,468 10/29/20
Bonvini Ezio Sr VP, Research & CS.. Sr VP, Research & CSO Sep 21 Sell 30.94 62,851 1,944,610 83,807 09/21/20